Why Is SciSparc Ltd. Ordinary Shares (SPRC) Stock Up 198.2% Today?

SciSparc Ltd. Ordinary Shares (SPRC) is having a historic day. The stock exploded 198.2% to $13.09 on Thursday, May 28, 2026, after climbing from a previous close of $4.39. Trading volume hit 15,215,337 shares—an astonishing 5,664x the 30-day average of 2,688,000 shares. The catalyst: NeuroThera Labs, SciSparc's majority-owned subsidiary, signed a definitive agreement to acquire a majority stake in CliniQuantum, an innovator in quantum-based clinical trial analysis. This is why is SPRC stock up today—and the move reflects investor enthusiasm for a potential game-changing asset in drug development.

What's Driving SPRC Stock Up Today

NeuroThera Labs, in which SciSparc holds a 75% stake, signed a definitive agreement to acquire a majority position in CliniQuantum. This acquisition represents a significant strategic pivot for SciSparc's portfolio. CliniQuantum specializes in quantum algorithm-based biodata analysis—applying quantum computing to accelerate clinical trial design, patient stratification, and data analysis. The deal structure remains partial owner, giving NeuroThera operational control while maintaining majority equity.

This isn't SciSparc's first move in quantum biotech. The company signed a non-binding term sheet with CliniQuantum back in December 2025, signaling management's conviction in the asset. Moving from term sheet to definitive agreement in roughly five months demonstrates rapid deal progression. The quantum clinical trials space is nascent but potentially transformative—faster trial execution could reduce time-to-market for drugs and lower development costs for sponsors.

SciSparc's strategy has shifted toward acquisitions and portfolio consolidation. In October 2025, the company entered a definitive agreement to acquire a publicly traded TSXV company and transfer its advanced clinical-stage pharmaceutical assets. Just months earlier, in September 2025, shareholders approved a merger between SciSparc's majority-owned subsidiary MitoCareX and N2OFF, consolidating cancer drug discovery assets. The CliniQuantum deal fits this pattern: building a tech-enabled platform for drug development rather than relying solely on traditional pharma R&D.

The 198% move reflects both the extreme illiquidity of SPRC shares and market recognition that quantum-based clinical tools could have wide application across the industry. At $13.09, the stock is trading 197% above yesterday's close—a move that typically occurs only when investors see transformational news. However, readers should note that market cap and liquidity matter more than percentage moves; SPRC remains a micro-cap with thin trading conditions.

SPRC Stock Key Levels to Watch

SPRC's intraday range today was $11.87 to $14.29. The stock opened at $4.39 and rallied relentlessly, hitting an intraday high of $14.29 before settling near $13.09. Current resistance sits at the $14.29 high established earlier today. Below that, $12.00 is a secondary support level from the day's low.

The 52-week context matters here: without current 52-week high/low data publicly available for SPRC on May 28, 2026, assume this $14.29 intraday high represents a multi-year peak for the stock. The stock was trading at $4.39 just one day ago, so any level above $4.50 is new territory for recent traders. Understanding stock chart levels helps identify where momentum may pause or reverse.

Volume analysis is critical here. At 15.2M shares traded versus a 30-day average of 2.7M shares, today's volume is extraordinarily high—a 5,664% ratio. This extreme volume typically confirms the conviction behind the move but also warns of potential volatility and liquidity constraints on position sizing. If investors want to exit, they may face wider spreads on large orders.

What Analysts Say About SPRC Stock

Current analyst coverage on SPRC is limited. The stock trades on the NASDAQ as a micro-cap biotech play and does not have extensive Wall Street coverage. However, the CliniQuantum acquisition signals a strategic shift that could attract biotech-focused analysts. Prior to this deal, SPRC was viewed primarily as a cannabinoid pharmaceutical developer—a competitive space with limited near-term catalysts. The quantum clinical trial angle is novel and may generate fresh research interest.

Until formal analyst coverage emerges post-deal, the market itself is pricing in significant upside. The 198% move suggests bull-case investors are betting on: (1) quantum-based trial platforms gaining traction with pharma sponsors, (2) NeuroThera Labs capturing a meaningful share of the emerging quantum biotech market, and (3) a potential acquisition or partnership that could yield outsized returns for shareholders.

Bear-case risks include execution delays, quantum computing failing to deliver clinical trial acceleration in practice, financing challenges if the deal requires capital raises, and shareholder dilution. Investors should monitor Form 8-K filings for detailed deal terms.

What's Next for SciSparc Stock

The immediate catalyst is deal closure. SciSparc has not disclosed a timeline for closing the CliniQuantum acquisition, but definitive agreements typically close within 3-9 months pending regulatory approval and working capital adjustments. The company will likely provide details on the next earnings call or via press release.

Bull case: CliniQuantum's platform gains rapid adoption among drug sponsors. Trial timelines compress by 20-30%, driving cost savings. SciSparc becomes a strategic asset in the quantum biotech space, attracting partnership or acquisition interest from larger pharma. Fair value target: $25-35 per share within 18 months, representing 90-170% upside from today's levels.

Bear case: Quantum computing proves slower to integrate into real-world clinical workflows. Deal requires significant capital raises, diluting existing shareholders. Competitive pressure emerges from larger tech companies entering quantum biotech. Stock retreats to $6-8 per share, representing a 45-54% downside from today.

Key milestones to watch: (1) Deal closure announcement—likely Q3-Q4 2026; (2) First pharma partnership or pilot program with CliniQuantum—could validate the platform; (3) SciSparc's next quarterly earnings (check the earnings calendar for the exact date) for financing structure details.

Frequently Asked Questions

Why is SPRC stock up today?

SciSparc's 75%-owned subsidiary NeuroThera Labs signed a definitive agreement to acquire a majority stake in CliniQuantum, a quantum algorithm-based clinical trial platform. The deal signals SciSparc's pivot from traditional pharma development to quantum-enabled drug development infrastructure. Investors are pricing in significant value creation if the platform gains adoption among drug sponsors.

What is CliniQuantum?

CliniQuantum is a biotech innovator specializing in quantum algorithm-based analysis for clinical trials. The platform applies quantum computing to streamline trial design, patient stratification, and biodata analysis—potentially reducing development timelines and costs for pharmaceutical companies.

Is SPRC stock a buy right now?

This is a highly speculative position. Analysts do not have consensus coverage, and the company is pre-revenue on the CliniQuantum platform. The 198% move in one day reflects extreme volatility typical of micro-cap biotech. Readers should consult a financial advisor and understand that positions in early-stage quantum biotech carry significant execution risk and loss potential.

What is the SPRC stock price target?

Without formal analyst coverage, no consensus price target exists. The intraday high of $14.29 represents the market's current bid. Bull-case investors may target $25-35 within 18 months if the platform gains traction; bear-case targets are $6-8 if execution falters. Current price is $13.09.

When will the CliniQuantum deal close?

SciSparc has not disclosed a closure timeline. Definitive agreements typically close within 3-9 months. Watch for updates on earnings calls and SEC filings. The company will likely announce closure milestones via 8-K or press release.

Bottom Line

SPRC's 198% surge reflects market recognition that quantum-based clinical trial platforms could be transformational. NeuroThera Labs' definitive agreement to acquire CliniQuantum is a bold bet on an emerging technology. However, the stock's extreme illiquidity (5,664x average volume today) and micro-cap status make this a speculation, not an investment. Execution risk is high: quantum computing may not deliver real-world clinical trial acceleration, the deal may require dilutive financing, or competitive pressure may erode the platform's value.

For traders: Monitor SPRC for technical support at $12.00 and resistance at $14.29 into the next session. For long-term investors: Wait for deal closure details, first pharma partnerships, and analyst coverage before sizing positions. The quantum biotech space is nascent, and SciSparc is a pre-revenue play on unproven technology. Watch the earnings calendar for Q2 results—management will provide critical deal financing and timeline updates. Until then, expect continued volatility as the market prices in different scenarios.